The ability to identify prostate tumor or prostate tissue specific genes that are expressed at high levels and use their protein products as targets could greatly aid in the diagnosis and treatment of prostate cancer. Using a polymerase chain reaction (PCR)-based subtraction technique, we have recovered the recently described KLK4 (prostase) gene from human prostate cDNA. In this study, KLK4 gene expression in human prostate tumors was further characterized using cDNA quantitative PCR and immunohistochemistry, demonstrating that the gene is specifically expressed at both the mRNA and protein levels in normal human prostate tissue, and in both primary and metastatic prostate tumor samples. Quantitative mRNA analysis also demonstrated low level expression including adrenal gland, salivary gland and thyroid. Finally, it was demonstrated that prostate cancer patient sera contain antibodies that bind specifically to recombinant KLK4 protein. This antibody has been used to detect KLK4-specific peptides in epitope mapping experiments. The relatively specific expression profile and elevated level of KLK4 mRNA and protein in both tumor and normal prostate tissues, in addition to detectable KLK4-specific antibody in cancer patient sera, supports additional efforts to determine if KLK4 can play a role in the diagnosis of prostate cancer, the monitoring of residual disease, or act as a target for immunotherapy. Oncogene (2002 Oncogene ( ) 21, 7114 -7120. doi:10.1038 Keywords: antibody; KLK4; prostase; prostate cancer; protein expression Prostate cancer is the most common cancer among men, and is the second leading cause of male cancer deaths in the US (Grenlee et al., 2000) . The current treatment options include prostatectomy or prostate ablation by radiation therapy. Either technique can fail to eliminate all tumor cells, resulting in recurrence of disease. This possibility is increased if diagnosis of prostate cancer is made late, with extracapsular involvement.
A number of human prostate-specific antigens have previously been identified, including prostate-specific antigen (PSA), prostatic acid phosphatase and prostate-specific membrane antigen. PSA is currently a well-established clinical marker as an indicator for prostate cancer (Daher and Beaini, 1998) , with the advantages that it is secreted and enters the circulatory system, and that virtually all primary prostate tumors maintain PSA expression. Increasing levels of PSA in peripheral blood has been shown to be an effective clinical marker useful in detecting the presence of prostate cancer, either in the initial diagnosis or in the detection of disease progression following procedures such as radical prostatectomy (Abi-Aad et al., 1992) . However, two problematic issues remain with utilizing PSA as a marker for the diagnosis of prostate cancer and the detection of residual disease. First, there is a high level of false positive tests due to PSA expression in benign prostatic hyperplasia that result in unnecessary biopsies. Second, PSA can fail as a marker for residual disease since not all metastases maintain expression of PSA (Daher and Beaini, 1998; Sissons et al., 1992) , and the presence of the PSA gene by reverse transcription (RT) -PCR from blood does not unequivocally indicate specific prostatic metastases (Thiounn et al., 1997) . Due to these limitations, additional markers for prostate cancer are needed. Recently, an additional prostate-specific androgenregulated serine protease was identified, termed prostase (Nelson et al., 1999) , KLK-L1 (kallikreinlike1) (Yousef et al., 1999) and also KLK4 (Stephenson et al., 1999) . The initial characterization of this gene (Nelson et al., 1999) demonstrated that prostase mRNA expression is restricted to normal prostate tissue and the prostate tumor cell line LNCaP. The prostase cDNA was shown to encode a putative 254 amino acid polypeptide, and was radiation-hybridpanel mapped to chromosome 19q13, a region contain-ing several other serine proteases including three known human kallikreins (hK1, hK2 and hK3 [PSA] ). A genomic analysis of this region more precisely mapped and localized the prostase gene and the related positions of other known genes in the area including PSA, KLK1, KLK2, zyme and neuropsin (Yousef et al., 1999 ). An additional study mapped the kallikrein-related prostase gene to the KLK locus, and based upon sequence similarities and like-characteristics amongst the three human kallikrein genes, proposed prostase be designated the fourth human kallikrein (KLK4) (Stephenson et al., 1999) . Fluorescence in situ hybridization analysis confirmed the localization of KLK4, or PRSS17, to the long arm of human chromosome 19, and more specifically narrowed the gene 's location to 19q13.3?q13.4 (DuPont et al., 1999) .
In this study we quantitatively characterize KLK4 expression, extending the mRNA expression profile of KLK4 by examining primary and metastatic human prostate tumors as well as mRNA expression characteristics of a large panel of human cell lines. In addition, anti-KLK4 antibodies were generated and used to demonstrate that KLK4 is a secreted protein.
Using immunohistochemical analysis, the prostatespecific expression profile was confirmed at the protein level. Lastly, we demonstrate that sera from patients with prostate cancer contain antibody specific to recombinant KLK4 protein. Collectively, these findings suggest further evaluation of KLK4 as a diagnostic marker and as a potential therapeutic target.
To date, characterization of the expression of this new serine protease family member has focused on mRNA levels in human normal tissues and prostate tumor cell lines (Nelson et al., 1999; Yousef et al., 1999) , hormonal regulation of a human endometrial cancer cell line (Myers and Clements, 2001) , serous ovarian carcinomas (Dong et al., 2001 ) and on expression levels as an indicator of ovarian cancer patient prognoses (Obiezu et al., 2001) . In order to extend the characterization of the tissue-specific expression of KLK4, cDNA quantitative PCR was used to analyse the expression of KLK4 in a large panel of samples, including normal prostate, primary and metastatic prostate tumors, human cell lines and a large panel of normal tissues.
Quantitative PCR was performed to determine mRNA levels of KLK4 in a large panel of human cell lines ( Figure 1a ). KLK4 was found to be expressed in LnCaP prostate tumor cell lines, but not in DU145 or PC-3 prostate tumor cell lines, a finding consistent with previously published data (Nelson et al., 1999) . KLK4 was also found to be expressed in pooled normal prostate tissues as expected, but had no detectable expression in a large number of non-prostate tumor lines, including breast, colon, ovarian, and lung tumor cell lines. In addition, extremely low or no detectable expression was observed in non-prostate tumor samples, including pooled breast, colon, ovarian, and lung tumor tissue. Finally, extremely low expression was detected in normal breast tissues whereas no expression was detected in normal lung or colon tissue samples.
Quantitative PCR was then performed to determine mRNA levels of KLK4 in prostate tumors, normal prostates and other normal human tissues. As shown in Figure 1b , increased expression of KLK4 mRNA is evident in all 22 prostate tumors and all three normal prostate samples analysed. Elevated expression of KLK4 is evident in one metastatic prostate tumor sample (met-lymph node), and low but detectable expression is apparent in a second metastatic prostate tumor sample (met-ascites). Elevated expression of KLK4 is also evident in all three of the benign prostatic hyperplasia (BPH)-positive samples examined as compared to non-prostate samples. In addition, low but detectable levels of expression were observed in the normal adrenal, salivary and thyroid gland samples, while the remaining 29 normal tissues tested yielded exceedingly low or no detectable quantities of amplified KLK4 mRNA.
To characterize KLK4 expression at the protein level, both rabbit polyclonal antisera and monoclonal antibodies were produced. Recombinant KLK4 was generated by expression of a six histidine-tagged, Cterminal 159 amino acid fragment in E. coli and the product was purified using nickel-nitrilotriacetic acid (NTA) column chromatography for subsequent use as an immunogen in rabbits. Polyclonal antisera was tested for KLK4 specificity and then affinity purified for use in Western blot and IHC analysis.
To determine if the KLK4 gene encoded a secreted protein, it was cloned into the pcDNA3.1 mammalian expression vector and used to transfect HEK293 cells. Analysis of transiently transfected HEK293 cell lysates revealed the expression of an *22 kD protein that is recognized by the anti-KLK4 affinity purified rabbit sera (data not shown). Analysis of supernatants recovered from the same transfection revealed the expression of an *25 kD protein due to glycosylation. Furthermore, N-terminal amino-acid sequence analysis revealed the cleavage of the putative signal sequence (residues 1 -26) (Nelson et al., 1999) , retaining the presence of the four amino acid propeptide (SCSQ) indicating incomplete cleavage of the protein into its predicted active form (data not shown).
In order to assess KLK4 expression by immunohistochemistry methods, a monoclonal antibody (mAb) specific for KLK4 was generated and used to stain tissue sections. Figure 2 shows representative examples of KLK4 immunoreactivity in tissue sections derived from a prostate tumor and normal prostate. In both normal prostate and prostate tumor samples, KLK4 expression was predominantly restricted to the epithelial cells lining the ductal regions (Figure 2 , upper panels). Overall, KLK4 expression was typically granular, cytoplasmic and dispersed throughout the cell. Four different prostate cancer tumor samples and four normal prostate samples were analysed, all of which were positive for anti-KLK4 immunoreactivity. Breast cancer and normal kidney tissues were also stained with the anti-KLK4 mAb and showed no anti- Figure 1 Quantitative PCR analysis was performed on the Perkin-Elmer/Applied Biosystems (Foster City, CA, USA) GeneAmp 5700 Sequence Detection System. Matching primers were designed for KLK4 according to the Primer Express software program (Perkin-Elmer/Applied Biosystems). Primer sequences used were as follows: (5' primer: 5'-CTTGCTCGC-TAACGACCTCAT-3' and 3' primer: 5'-GCCAGAAACGAGGCAAGAGT-3'). Primer concentrations were 300 nM each. SYBR Green reaction mixes were generated according to manufacturer's protocol (Perkin-Elmer/Applied Biosystems). Each reaction contained 2 ml of diluted template. cDNA from RT reaction prepared as above was used as template diluted 1 : 10 for each gene of interest and 1 : 100 for human b-actin quantitation. The human b-actin primer sequences were (5' primer: 5'-ACTGGAACGGTGAAGGTGACA-3' and 3' primer: 5'-CGGCCACATTGTGAACTTTG-3') and were used in a similar manner to quantitate the presence of b-actin in the samples. A portion of KLK4 was used as the template control. It was isolated by using prostate-specific PCR-select cDNA (Clontech, Palo Alto, CA, USA). Suppression subtractive hybridization was performed using a pool of normal human prostate cDNA as the tester and a pool of 10 other normal human tissues as a driver (Diatchenko et al., 1996 (Diatchenko et al., , 1999 . . In addition, both pooled tumor (5 -10 samples) and pooled normal tissue (5 -10 samples) mRNAs were included from these tumor types. RNA was isolated from tissue samples by homogenization in Trizol reagent (Life Technologies, Rockville, MD, USA) and extracted as per manufacturer's protocol. cDNA was prepared from 26 mg of total RNA by incubating with 100 ng/ml oligo dT (Roche, Indianapolis, IN, USA) at 708C for 10 min followed by incubation at 428C for 1 h with 0.5 mM dNTP, 1000 units RNasin, 0.02 mM dithiothreitol and 2500 units of KLK4 immunoreactivity (Figure 2, lower panels) . In addition to these tissues, various other malignant and non-malignant tissues were examined with the intent of better defining the specificity of KLK4 expression. No anti-KLK4 immunoreactivity could be observed in cancerous lung tissue, or in normal lung, colon and liver tissue samples (data not shown). A summary of the relative levels of anti-KLK4 immunoreactivity is shown in Table 1 .
Furthermore, we have addressed whether or not prostate cancer patients have had KLK4-specific B-cell responses induced. Although normal prostate epithelial cells express KLK4 at the protein level, it is known that tumor regions are frequently associated with inflammation and invasion of inflammatory cells. Given this information, we asked if prostate tumor patient sera contain antibodies specific to KLK4.
Initially, eight prostate cancer patient sera and eight normal donor sera were pooled and examined for the existence of Abs specific to KLK4 protein. The pooled sera (1000-fold dilution) of either patient or normal donor sera were used in the Western blot analysis. The pooled patient sera recognized a KLK4-specific band Figure 2 Immunohistochemistry analysis of KLK4 expression in prostate tumor and normal tissues. Representative examples of KLK4 expression in prostate cancer (upper left), normal prostate (upper right), breast cancer (lower left) and kidney (lower right). Rabbits (R and R Rabbitry, Stanwood, WA, USA) were immunized with 400 mg of purified, E. coli-generated KLK4 in 1 ml of incomplete Freund's adjuvant (IFA; Bethesda Research Laboratories) together with 100 mg of muramyl dipeptide (Calbiochem) delivered s.c. Rabbits were boosted 4 weeks later with 200 mg of recombinant KLK4 protein emulsified in 1 ml IFA, followed by i.v. every 4 weeks with 100 mg of soluble recombinant KLK4 protein. KLK4-specific antisera was purified by affinity chromatography against the E. coli-derived recombinant KLK4 antigen. Anti-KLK4 specific monoclonal antibodies were generated from the same immunized rabbits using the selected lymphocyte activation method (Babcook et al., 1996) . For immunohistochemistry, paraffin-embedded formalin fixed tissue was sliced into eight micron sections. Steam heat induced epitope retrieval (SHIER) in 0.1 M sodium citrate buffer (pH 6.0) was used for optimal staining conditions. Sections were incubated with 10% serum/PBS for 5 min. Primary antibody was added to each section for 25 min at indicated concentrations followed by a 25 min incubation with either an anti-rabbit or anti-mouse biotinylated antibody. Endogenous peroxidase activity was blocked by three 1.5 min incubations with hydrogen peroxidase. The avidin biotin complex/horse radish peroxidase (ABC/HRP) system was used along with DAB chromogen to visualize antigen expression. Slides were counterstained with hematoxylin Superscript II (Life Technologies). Relative expression levels of KLK4 for the given samples are shown in copies of KLK4/ng bactin. (b) KLK4 mRNA expression levels in human prostate tumor tissues, prostate normal tissues and an extensive panel of normal tissues. Relative expression levels of KLK4 for the given samples are shown in copies of KLK4/ng b-actin at the predicted molecular weight (*30 kDa) of an NS1-KLK4 fusion protein consisting of the mature KLK4 protein fused to the 8 kD NS1 protein, while the pooled sera of normal donors did not reveal any specific signal (Figure 3a) . The rabbit polyclonal KLK4-specific antisera was used as a positive control, reacting strongly with the NS1-KLK4 protein, but not NY-ESO-1 (Chen et al., 1997) , a control protein (Figure 3b) . In Figure 3c , Western blot analysis of individual patient's sera were shown, and patient sera #1, #2 and #3 but not #4 contain Abs specific to the NS1-KLK4 fusion protein. These data have also been confirmed using baculoviral-KLK4 protein, which contained no fusion partner or tags (data not shown).
It is therefore likely that the NS1-KLK4-specific Abs observed in these prostate patients are specific to KLK4 and not to NS1. Next, the sera of 20 prostate cancer patients and 13 normal male donors were assessed by ELISA for the existence of antibodies specific to the NS1-KLK4 protein.
As a negative control, BSA was assayed in parallel. As shown in Table 2 , the ELISA data demonstrated that seven of 20 prostate cancer patients have antibodies specific to the NS1-KLK4 antigen. Sera #1 through #4 correspond with those patients examined by Western blot (Figure 3c) , and the ELISA results correlate with those results. In marked contrast, none of the 13 normal donors had NS1-KLK4-specific antibodies.
Lastly, in order to further confirm the specificity of these Abs in patients, epitope-analysis using KLK-4 peptides was instigated using patient sera. As a negative control, normal donors' sera were also set in Figure 3 Western blot observation of KLK4-specific antibodies in prostate cancer patient sera but not in normal donor sera. Eight prostate cancer patient sera and eight normal male donor sera have been assayed for the existence of antibodies (Abs) specific to NS1-KLK4 fusion protein and NY-ESO-1-Histidine tag protein purified form E. coli. Each protein (200 ng/ lane) was electrophoresed, then blotted to nitrocellulose membrane. After blocking membranes with 10% NFDM/PBS, pooled sera or individual sera were incubated with the membranes. After washing with PBS/Tween and incubating with HRP-conjugated goat anti-human IgG, the membranes were developed by chemo-luminescence substrate. MM indicates molecular weight in kD Table 2 KLK4-specific Ab-positives in prostate cancer patients and normal donors. Twenty sera from prostate cancer patients and 13 normal male donors have been assayed for the presence of antibodies specific to NS1-KLK4-Histidine-tag protein made in E. coli. Wells of a 96-flat-well Nunc plate were coated with 200 ng of protein in 0.1 M carbonate buffer (pH 9.5), then blocked with 10% (w/v) non-fat dry milk (NFDM)/PBS. Patient and normal donor sera was diluted 300-fold with 10% goat sera/PBS, added to the wells and incubated at 48C overnight. In parallel, bovine serum albumin (BSA) was used as the negative control. The ELISA was developed with HRP-conjugated anti-human IgG and monitored at 450 nm absorption. The signal values considered positive (+) are 53-times higher than the mean value obtained from the wells coated with BSA Prostate cancer KLK4-specific Normal KLK4-specific patients antibody donors antibody
parallel. Patient #1 and #7 have Abs specific to NS1-KLK4 ( Figure 3c , Table 2 ), and both sera also recognized Bac-KLK4 by Western blot analysis (data not shown). These sera and two sera from normal donors were assessed for specific Abs by KLK4-peptide-based ELISA, wherein 96-well plates were coated with 0.5 mg of individual peptide covering the KLK4 coding sequence (Nelson et al., 1999) . As shown in Figure 4a , both sera recognized one specific peptide (aa229-aa244). In contrast, the normal donor sera did not have specific binding to this KLK4 peptide ( Figure  4b ). The recent discovery and reporting of KLK4 by four other groups (DuPont et al., 1999; Nelson et al., 1999; Stephenson et al., 1999; Yousef et al., 1999) has resulted in some question of the specificity of mRNA expression of this gene. Herein, we clarify the level of mRNA expression in prostate tumors, normal prostate, and non-prostate normal tissues. Using a quantitative PCR method and normalizing results using human actin mRNA expression, we have determined that mRNA expression is significantly elevated in both normal prostate and prostate tumors, compared to all other normal tissues tested. However, low levels of KLK4 mRNA expression were detected in three normal human glandular tissues -adrenal, salivary and thyroid. In contrast to data reported by Nelson et al. (1999) we do not detect elevated expression in small intestine. Additionally, we have demonstrated that this expression is retained both in primary prostate tumors of various stage and grade and is also maintained in two metastatic prostate samples.
The demonstration of KLK4 mRNA expression in all of the primary prostate tumors and metastatic samples tested indicates a potential role for use of this transcript for diagnosis and monitoring for residual disease by RT -PCR amplification from patient blood. Potential for this type of diagnosis has been demonstrated for the mammaglobin gene in metastatic breast cancer (Houghton et al., 2001; Watson et al., 1999) .
We have also examined various human tissue preparations with a KLK4-specific monoclonal antibody by immunohistochemistry. This analysis indicates that the KLK4 protein expression determined thus far has the same restricted expression pattern as that found for KLK4 mRNA. Both a bioinformatic analysis protein prediction program (PSORT) (Nakai and Kanehisa, 1992) and the relatively high level of homology to secreted serine proteases, argues that KLK4 is a secreted protein. The demonstration of KLK4 secretion from transfected HEK293 cells is consistent with this prediction. Although this study confirms the potential for KLK4 to be secreted, this has yet to be confirmed in either normal or malignant prostate tissues. Our attempts to detect KLK4 protein in LNCaP cells were Figure 4 Epitope-analysis of KLK4-specific Abs in prostate cancer patients and normal donors' sera. Prostate cancer patient sera #1 and #7 were diluted 300-fold with 5% goat sera and 5% NFDM-containing PBS. They were incubated in 96-well plate (Nunc, Denmark) wherein individual KLK4 peptides were coated with bicarbonate buffer (9.5) and blocked with 10% NFDM/PBS. After washing plates, HRP-conjugated anti-human IgG Abs (Jackson ImmunoResearch, West Grove, PA, USA) was used for developing ELISA as described in the legend to Table 2 unsuccessful. It is also not known if KLK4 enters the circulation in individuals with a normally functioning prostate, benign prostatic hyperplasia, or prostate cancer. While the secretion of the KLK4 protein has not been unambiguously established, the evidence presented here does indicate that the KLK4 protein is recognized by the immune system of prostate cancer patients, with the generation of KLK4-specific antibody.
